1WHO. State of the World's Vaccines and Immunization[R]. 2002. 被引量：1
2WHO Department of Immunization, Vaccines and Biologicals. Core information for the development of immunization policy 2002 update[M]. Geneva,World Health Organisation. 2003. 被引量：1
3WHO. Global progress towards universal childhood hepatitis B vaccination, 2003[J]. Wkly Epidemiol Rec, 2003,78 (42): 366 - 370. 被引量：1
4Global Alliance for Vaccines and Immunization.GAVI Milestones,2003.Available at http://www.vaccinealliance.org/home/General Information/About alliance/Background/milestones. Php 被引量：1
5Ribot S, Rothstein M, Goldblat M, et al. Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med, 1979,139:178 被引量：1
6V alderrabano F, Berthoux FC, Jones EH, et al. Report on managment of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant, 1996(Suppl 1),11:2 被引量：1
7McAdam A J, Schweiter AN, Sharpe AH. The role of B7 cosfimulation in activation and differentiation of CD4+ and CD8+ T cells, Immunol Rev,1998, 165:231 被引量：1
8Schweitzer AN, Sharpe AH. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2(CD86) show distinct requirements for B7 nolecules during priming versus restimulation of Th2but not Thl cytokine production. J lmmunol, 1998,161:2762 被引量：1
9Henry J, Miller MM, Pontarotti P. Structure and evolution of the extended B7 family. Immunol Today, 1999,20:285 被引量：1
10Meuer SC, Hauer M, Kurz P, et al. Selective blockade of the antigenreceptor-mediated pathway of T cell activation in patients with impaired innune responses. J Clin Invest, 1987,80: 743 被引量：1
1Tokars JI, Miller ER, Alter M J, et al. National Surveillance of Dialy- sis ssociated Disease in the United Satates, 1996[J]. Atlanta: Cen- ters for Disease Controland Prevention, 1998: 1-59. 被引量：1
2Seaworth B, Drucker J, Starling J, et al. Hepatitis B Vaccines in pa- tients with chronicrenal failure before dialysis[J]. J Infect Dis, 1988, 157: 332-337. 被引量：1
3Allegra V, Vasile A, Maschio M. Immune response aftervaccination with recombinant hepatitis surface antigen in maintence haemilialy- sis surface antigen in maintenance haemolialysis patients and healthy controls[J]. Nephron, 1992, 61: 339-340. 被引量：1
4Ramezani A, Eslamifar A, Banifazl M, et al. Efficacy and longterm immunogenicity of hepatitis B vaccine in haemodialysis patients[J]. Int J Clin Pratt, 2009, 63: 394-397. 被引量：1
5Femandez E, Betriu MA, Gomez R, et al. Response to the heptitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality[J]. Nephrol. Dial Transplant, 1996, 11 : 1559-1563. 被引量：1
6Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis[J]. Nephron, 1996, 72: 534-543. 被引量：1
